Regenxbio plans USD 100 million follow-on common stock offering
RGNX•Regenxbio launches follow-on offering
Regenxbio launched an underwritten public offering of USD 100 million of common stock, subject to market conditions.
Underwriters received a 30-day option to buy up to 15% more shares.
Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho were named joint bookrunners.
